Status:
RECRUITING
Evaluation of Effectiveness and Safety of Hybrid Coronary Revascularization
Lead Sponsor:
Seung-Jung Park
Collaborating Sponsors:
CardioVascular Research Foundation, Korea
Conditions:
Percutaneous Coronary Revascularization
Coronary Stenosis
Eligibility:
All Genders
20+ years
Brief Summary
This study evaluated the effectiveness and safety of Hybrid Coronary Revascularization in real-world practice.
Eligibility Criteria
Inclusion
- Age 20 and more
- Hybrid coronary revascularization due to multivessel coronary artery disease(must include left anterior descending artery)
- Written consent
Exclusion
- Previous CABG(coronary artery bypass graft)
- Life expectancy ≤1 year
Key Trial Info
Start Date :
April 5 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2030
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03788369
Start Date
April 5 2019
End Date
December 1 2030
Last Update
January 2 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea